Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

271
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
271
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

359
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
359
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

316
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
316
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

219
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
219
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
142

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Closing the Global Action Plan is not Reasonable for the Materiai in My Commentary that States Closing the Gap.

Epilepsy currents·2026
Same author

Amygdala enlargement in pediatric epilepsy: A clinically meaningful finding?

Epilepsy research·2026
Same author

NINDS: Celebrating 75 Years of Advancing Epilepsy Research.

Epilepsy currents·2026
Same author

Ask a Simple Question, Design an Elegant Study and the Rest is History.

Epilepsy currents·2026
Same author

In the Quest for Answers: Exploring Circumstances Around Pediatric SUDEP.

Epilepsy currents·2025
Same author

Special Considerations for Personalization in Pediatric Intracranial Neuromodulation.

Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society·2025

Related Experiment Video

Updated: May 29, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.5K

Pediatric Epilepsy Management: Special Considerations.

Katherine Nickels1, Charuta Joshi2

  • 1Department of Neurology, Mayo Clinic, Rochester, Minnesota.

Seminars in Neurology
|February 4, 2025
PubMed
Summary

Pediatric epilepsy presents unique challenges due to the developing brain, affecting syndromes, treatments, and comorbidities. Special considerations are vital for managing childhood epilepsy and its long-term impact.

More Related Videos

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

20.1K

Related Experiment Videos

Last Updated: May 29, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

2.5K
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

20.1K

Area of Science:

  • Neurology
  • Pediatrics
  • Epileptology

Background:

  • Pediatric epilepsy differs from adult epilepsy due to the unique characteristics of the growing brain.
  • Childhood epilepsy involves distinct etiologies, syndromes, comorbidities, and treatment approaches.
  • Long-term effects of epilepsy and its treatments in children require careful consideration.

Purpose of the Study:

  • To highlight unique considerations for pediatric epilepsy management.
  • To discuss specific pediatric-onset epilepsy syndromes and their treatment durations.
  • To address developmental, psychiatric, and behavioral comorbidities in children with epilepsy.

Main Methods:

  • Review of unique aspects of pediatric epilepsy.
  • Discussion of pediatric-onset electroclinical syndromes.
  • Analysis of etiology-specific treatments and commonly used pediatric therapies.

Main Results:

  • Pediatric epilepsy involves syndromes that often resolve in adulthood.
  • Etiology-specific treatments and specialized pediatric therapies are crucial.
  • Bidirectional relationships exist between pediatric epilepsy and developmental/psychiatric comorbidities.

Conclusions:

  • Pediatric epilepsy necessitates tailored management strategies considering the developing brain.
  • Transitioning care from pediatric to adult services presents unique challenges.
  • Special issues like limited pediatric FDA approvals and sedation needs impact pediatric epilepsy care.